File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3978/j.issn.2218-6751.2015.07.22
- Scopus: eid_2-s2.0-84960095714
- WOS: WOS:000421753700013
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Triaging early-stage lung cancer patients into non-surgical pathways: Who, when, and what?
Title | Triaging early-stage lung cancer patients into non-surgical pathways: Who, when, and what? |
---|---|
Authors | |
Keywords | Surgery Stereotactic body radiation therapy (SBRT) Radiofrequency ablation (RFA) Operable Central Inoperable Non-small cell lung cancer (NSCLC) |
Issue Date | 2015 |
Citation | Translational Lung Cancer Research, 2015, v. 4, n. 4, p. 438-447 How to Cite? |
Abstract | © Translational lung cancer research. All rights reserved. More lung cancer patients are being diagnosed at an earlier stage due to improved diagnostic imaging techniques, a trend that is expected to accelerate with the dissemination of lung cancer screening. Surgical resection has always been considered the standard treatment for patients with early-stage non-small cell lung cancer (NSCLC). However, non-surgical treatment options for patients with early-stage NSCLC have evolved significantly over the past decade with many new and exciting alternative treatments now available. These alternative treatments include radiofrequency ablation (RFA), microwave ablation (MWA), percutaneous cryoablation therapy (PCT), photodynamic therapy (PDT) and external beam radiation therapy (EBRT), including stereotactic body radiation therapy (SBRT) and accelerated hypofractionated radiation therapy. We describe the established alternatives to surgical resection, their advantages and disadvantages, potential complications and efficacy. We then describe the optimal treatment approach for patients with early-stage NSCLC based on tumor operability, size and location. Finally, we discuss future directions and whether any alternative therapies will challenge surgical resection as the treatment of choice for patients with operable early-stage lung cancer. |
Persistent Identifier | http://hdl.handle.net/10722/267025 |
ISSN | 2023 Impact Factor: 4.0 2023 SCImago Journal Rankings: 1.318 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sroufe, Rameses | - |
dc.contributor.author | Kong, Feng Ming | - |
dc.date.accessioned | 2019-01-31T07:20:17Z | - |
dc.date.available | 2019-01-31T07:20:17Z | - |
dc.date.issued | 2015 | - |
dc.identifier.citation | Translational Lung Cancer Research, 2015, v. 4, n. 4, p. 438-447 | - |
dc.identifier.issn | 2218-6751 | - |
dc.identifier.uri | http://hdl.handle.net/10722/267025 | - |
dc.description.abstract | © Translational lung cancer research. All rights reserved. More lung cancer patients are being diagnosed at an earlier stage due to improved diagnostic imaging techniques, a trend that is expected to accelerate with the dissemination of lung cancer screening. Surgical resection has always been considered the standard treatment for patients with early-stage non-small cell lung cancer (NSCLC). However, non-surgical treatment options for patients with early-stage NSCLC have evolved significantly over the past decade with many new and exciting alternative treatments now available. These alternative treatments include radiofrequency ablation (RFA), microwave ablation (MWA), percutaneous cryoablation therapy (PCT), photodynamic therapy (PDT) and external beam radiation therapy (EBRT), including stereotactic body radiation therapy (SBRT) and accelerated hypofractionated radiation therapy. We describe the established alternatives to surgical resection, their advantages and disadvantages, potential complications and efficacy. We then describe the optimal treatment approach for patients with early-stage NSCLC based on tumor operability, size and location. Finally, we discuss future directions and whether any alternative therapies will challenge surgical resection as the treatment of choice for patients with operable early-stage lung cancer. | - |
dc.language | eng | - |
dc.relation.ispartof | Translational Lung Cancer Research | - |
dc.subject | Surgery | - |
dc.subject | Stereotactic body radiation therapy (SBRT) | - |
dc.subject | Radiofrequency ablation (RFA) | - |
dc.subject | Operable | - |
dc.subject | Central | - |
dc.subject | Inoperable | - |
dc.subject | Non-small cell lung cancer (NSCLC) | - |
dc.title | Triaging early-stage lung cancer patients into non-surgical pathways: Who, when, and what? | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.3978/j.issn.2218-6751.2015.07.22 | - |
dc.identifier.scopus | eid_2-s2.0-84960095714 | - |
dc.identifier.volume | 4 | - |
dc.identifier.issue | 4 | - |
dc.identifier.spage | 438 | - |
dc.identifier.epage | 447 | - |
dc.identifier.eissn | 2226-4477 | - |
dc.identifier.isi | WOS:000421753700013 | - |
dc.identifier.issnl | 2218-6751 | - |